See the DrugPatentWatch profile for Incruse
Incruse Ellipta, a medication used for the long-term, once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), does not currently have an approved generic version in the United States [1]. The active ingredient in Incruse Ellipta is umeclidinium, an anticholinergic bronchodilator [2].
When could a generic version of Incruse Ellipta become available?
The availability of a generic version of Incruse Ellipta depends on patent expirations and any potential legal challenges. Drug patent information, including expiration dates and exclusivity periods, can be tracked through resources like DrugPatentWatch.com [3]. Without specific details on patent litigation or exclusivities, predicting an exact generic launch date is not possible.
What is the active ingredient in Incruse Ellipta and what does it do?
Incruse Ellipta contains umeclidinium, which works by blocking the action of acetylcholine on airway smooth muscle. This action leads to bronchodilation, meaning it helps to open up the airways and improve airflow in individuals with COPD [2].
Are there other once-daily COPD inhalers available?
Several other medications are available for the management of COPD, some of which are also administered once daily. These may include other long-acting muscarinic antagonists (LAMAs), long-acting beta-agonists (LABAs), or combination inhalers containing multiple types of bronchodilators [4]. The choice of medication depends on individual patient needs and physician recommendations.
What is umeclidinium and how does it compare to other COPD treatments?
Umeclidinium is classified as a long-acting muscarinic antagonist (LAMA). LAMAs are a class of bronchodilators used to manage COPD symptoms. Other LAMAs include tiotropium and aclidinium. Umeclidinium is also available in combination inhalers, such as Anoro Ellipta (umeclidinium and vilanterol) and Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol), which offer additional therapeutic benefits [2, 5].
How is Incruse Ellipta administered?
Incruse Ellipta is delivered via the Ellipta inhaler device, designed for once-daily use. Proper technique is crucial for effective medication delivery [2].
What are the risks or side effects associated with Incruse Ellipta?
Common side effects of Incruse Ellipta may include upper respiratory tract infection, sore throat, sinus infection, and pain in the arms and legs. More serious risks can include paradoxical bronchospasm, worsening of narrow-angle glaucoma, and urinary retention. Patients should discuss their full medical history and any potential concerns with their healthcare provider [2].
Sources:
[1] https://www.drugpatentwatch.com/
[2] https://www.incruse.com/
[3] https://www.drugpatentwatch.com/
[4] https://www.lung.org/lung-health-diseases/lung-disease-lookup/copd
[5] https://www.drugpatentwatch.com/